Target Information

Target General Infomation
Target ID
T27999
Former ID
TTDR00859
Target Name
Protective antigen
Gene Name
pagA
Synonyms
Anthrax toxins translocating protein; Bacillus anthracis protective antigen; PA; PA-83; PA83; pagA
Target Type
Successful
Disease Anthrax [ICD9: 22; ICD10: A00-B99]
Bacterial infections [ICD9: 001-009, 010-018, 020-027, 030-041, 080-088, 090-099, 100-104; ICD10: A00-B99]
Bacillus anthracis infection [ICD10: A22]
Function
One of the three proteins composing the anthrax toxin, the agent which infects many mammalian species and that may cause death. PA binds to a receptor (ATR) in sensitive eukaryotic cells, thereby facilitating the translocation of the enzymatic toxin components, edema factor and lethal factor, across the target cell membrane. PA associated with LF causes death wheninjected, PA associated with EF produces edema. PA induces immunity to infection with anthrax.
BioChemical Class
Bacillus anthracis protective antigen
UniProt ID
P13423
Sequence
MKKRKVLIPLMALSTILVSSTGNLEVIQAEVKQENRLLNESESSSQGLLGYYFSDLNFQA
PMVVTSSTTGDLSIPSSELENIPSENQYFQSAIWSGFIKVKKSDEYTFATSADNHVTMWV
DDQEVINKASNSNKIRLEKGRLYQIKIQYQRENPTEKGLDFKLYWTDSQNKKEVISSDNL
QLPELKQKSSNSRKKRSTSAGPTVPDRDNDGIPDSLEVEGYTVDVKNKRTFLSPWISNIH
EKKGLTKYKSSPEKWSTASDPYSDFEKVTGRIDKNVSPEARHPLVAAYPIVHVDMENIIL
SKNEDQSTQNTDSQTRTISKNTSTSRTHTSEVHGNAEVHASFFDIGGSVSAGFSNSNSST
VAIDHSLSLAGERTWAETMGLNTADTARLNANIRYVNTGTAPIYNVLPTTSLVLGKNQTL
ATIKAKENQLSQILAPNNYYPSKNLAPIALNAQDDFSSTPITMNYNQFLELEKTKQLRLD
TDQVYGNIATYNFENGRVRVDTGSNWSEVLPQIQETTARIIFNGKDLNLVERRIAAVNPS
DPLETTKPDMTLKEALKIAFGFNEPNGNLQYQGKDITEFDFNFDQQTSQNIKNQLAELNA
TNIYTVLDKIKLNAKMNILIRDKRFHYDRNNIAVGADESVVKEAHREVINSSTEGLLLNI
DKDIRKILSGYIVEIEDTEGLKEVINDRYDMLNISSLRQDGKTFIDFKKYNDKLPLYISN
PNYKVNVYAVTKENTIINPSENGDTSTNGIKKILIFSKKGYEIG
Drugs and Mode of Action
Drug(s) Raxibacumab Drug Info Approved Anthrax [531382]
AVP-21D9 Drug Info Phase 1 Bacillus anthracis infection [523172]
IQ-DAA Drug Info Phase 1 Bacillus anthracis infection [547984]
Valortim Drug Info Phase 1 Bacterial infections [523304]
Anthrax vaccine Drug Info Discontinued in Phase 1 Bacillus anthracis infection [547585]
Modulator IQ-DAA Drug Info
Raxibacumab Drug Info [531382]
Pathways
Pathway Interaction Database Cellular roles of Anthrax toxin
Reactome Uptake and function of anthrax toxins
References
Ref 523172ClinicalTrials.gov (NCT01202695) Safety and Pharmacokinetics Study of Human Monoclonal Antibody (AVP-21D9). U.S. National Institutes of Health.
Ref 523304ClinicalTrials.gov (NCT01265745) Dose Escalation Study of Valortim (MDX-1303) Administered Intravenously (IV) in Healthy, Normal Subjects. U.S. National Institutes of Health.
Ref 531382Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550). J Immunol. 2011 Apr 1;186(7):4234-43.
Ref 547585Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800017549)
Ref 547984Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800020942)
Ref 531382Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550). J Immunol. 2011 Apr 1;186(7):4234-43.
Ref 544207Phase I Study Evaluating the Safety and Pharmacokinetics of MDX-1303, a Fully Human Monoclonal Antibody against Bacillus anthracis Protective Antigen, in Healthy Volunteers. Clin Vaccine Immunol. 2011 December; 18(12): 2136-2142.
Ref 544420Efficacy and Safety of AVP-21D9, an Anthrax Monoclonal Antibody, in Animal Models and Humans. Antimicrob Agents Chemother. 2014 July; 58(7): 3618-3625.
Ref 551835Annual Reports in Medicinal Chemistry. Annette M. Doherty. 2005. Page(214).

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.